DDInter1330 DDInter1376
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Olmesartan {u} (Compound) resembles {v} (Compound) Forasartan
Olmesartan {u} (Compound) resembles {v} (Compound) Telmisartan
Olmesartan {u} (Compound) treats {v} (Disease) hypertension
Olmesartan {u} (Compound) binds {v} (Gene) AGTR1
Olmesartan {u} (Compound) causes {v} (Side Effect) Arthralgia
Olmesartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylprednisolone
Olmesartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin lispro
Olmesartan {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Olmesartan (Compound) resembles Forasartan (Compound)
Olmesartan (Compound) resembles Telmisartan (Compound)
Olmesartan (Compound) treats hypertension (Disease)
Olmesartan (Compound) binds AGTR1 (Gene)
Olmesartan (Compound) causes Arthralgia (Side Effect)
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro
Olmesartan may lead to a major life threatening interaction when taken with Potassium chloride